Pfizer has made an investment of $21 million in order to upgrade Adelaide cancer drug manufacturing facility.
Pfizer announced on Thursday of its decision to invest $21 million in the renovation and upgrades of the facility that is going to manufacture drugs and medication for cancer in Adelaide, South Australia. This facility will play a huge part in manufacturing and producing the drug, pegfilgrastim, which is going to be utilized in the stimulation of white blood cells in patients who have been diagnosed with cancer.
The pharmaceutical company’s site director for Adelaide, Dr. Tony Mulcahy informed that another manufacturing center situated in Thebarton is going to bring $380 million to the economy of South Australia in the coming seven years. 100 employees are expected to work in the production of the drug, pegfilgrastim.
Pegfilgrastim is going to help cancer patients by stimulating white blood cells and help them deal with chemotherapy without further problems and complications. Cancer treatment makes the immune system of patients completely fail, which leads to an awfully low count of white blood cells in the body of the patient. This makes the patient more vulnerable to other infections and diseases, which can even lead to death since the immune system is not strong enough to fight back even minor infections.
This investment by Pfizer Inc. in Adelaide facility is going to make the center first one ever of such kind in the area. This plant might reach completion and will be operational in 2017. Managing director, David Gallagher, believes this to be a welcoming move. Once this plant is complete, it is going to become one of the largest biologic medicine centers in the region. Renovations will be complete on April 29, while the validation might take up to four months.
Other health companies in Australia are helping the pharma giant in negotiations, so that the company can deal with the regulators easily while manufacturing side by side. The pharmaceutical organization is going to work with its other facility in Zagreb, where the manufactured product, Pegfilgrastim developed in Adelaide, is going to be put into syringes.
Pfizer has never hesitated when it comes to research and development of the best possible and innovative forms of medications and treatments to make human lives better and healthy and is not going to stop now either.
Millions of people around the world will be able to utilize this produce of the medicinal company. The upgraded Adelaide center is going to be the national hub for the production of this drug.
